@article {SherPA3733, author = {Lawrence Sher and Giovanni Passalacqua and Camille Taill{\'e} and Lauren Cohn and Santiago Quirce and Nadia Daizadeh and Nami Pandit-Abid and Benjamin Ortiz and Asif H. Khan and Yi Zhang}, title = {Effect of dupilumab on patient-reported sleep outcomes in patients with severe asthma}, volume = {58}, number = {suppl 65}, elocation-id = {PA3733}, year = {2021}, doi = {10.1183/13993003.congress-2021.PA3733}, publisher = {European Respiratory Society}, abstract = {Background: The Asthma Quality of Life Questionnaire (AQLQ) includes items assessing the impact of asthma on sleep in patients (pts). Dupilumab (DPL), a fully human mAb, blocks the shared receptor component for IL-4/IL-13, key and central drivers of type 2 inflammation in multiple diseases. In phase 3 VENTURE (NCT02528214), DPL 300mg every 2 weeks (q2w) vs placebo (PBO) reduced oral corticosteroid (OCS) maintenance dose and rate of severe asthma exacerbations and improved pre-bronchodilator FEV1 and health-related quality of life in pts with OCS-dependent, severe asthma. DPL was generally well tolerated.Aim: To assess the effect of DPL on pt-reported sleep outcomes in VENTURE.Methods: Four AQLQ items assess the impact of asthma on sleep on a scale of 1{\textendash}7; scores of 6/7 indicate little/no impact of asthma. The proportion of pts with scores of 6/7 on the sleep-related items ($\#$5, $\#$20, $\#$24, and $\#$29) was evaluated at baseline (BL), Week (Wk) 12 and 24.Results: The proportion of pts reporting little/no impact of asthma on sleep-related items at BL was 17\%{\textendash}37\%, suggesting that most pts experienced sleep impairment. A greater proportion of DPL pts vs PBO reported little/no impact of asthma on sleep at Wk 24 (P\<0.01 for item $\#$20) (Figure).Conclusion: Pts with OCS-dependent, severe asthma had impaired sleep at BL. At Wk 24, a greater proportion of DPL pts reported waking up with asthma symptoms hardly any or none of the time vs PBO. FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3733.This abstract was presented at the 2021 ERS International Congress, in session {\textquotedblleft}Prediction of exacerbations in patients with COPD{\textquotedblright}.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).}, issn = {0903-1936}, URL = {https://erj.ersjournals.com/content/58/suppl_65/PA3733}, eprint = {https://erj.ersjournals.com/content}, journal = {European Respiratory Journal} }